National Institute of Biomedical Imaging and Bioengineering

Low-cost, customizable microscope takes top biomedical engineering prize

Newswise — The winners of National Institutes of Health’s 9th annual Design by Biomedical Undergraduate Teams (DEBUT) challenge developed simple and low-cost diagnostics and treatments for conditions such as tuberculosis, cervical cancer, birth defects, and onchocerciasis (river blindness). The DEBUT challenge, with prizes worth $100,000, is supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the National Institute on Minority and Health Disparities (NIMHD), and NIH Office of AIDS Research, parts of the NIH, and VentureWell, a non-profit higher-education network that cultivates revolutionary ideas and promising inventions.

DEBUT received 86 applications from 46 universities in 20 states, engaging a total of 410 students this year. NIBIB selected three winning teams for designs that excel according to four criteria: the significance of the problem being addressed; the impact on clinical care; the innovation of the design; and the existence of a working prototype. The prizes will be awarded in an online ceremony at the annual Biomedical Engineering Society (BMES) conference on October 15, 2020.

“The winners of this year’s DEBUT challenge show how students with a fresh perspective can develop innovative technologies that are low-cost and simple to use and yet can solve complex health challenges,” said Bruce Tromberg, Ph.D., NIBIB director. “It is exciting to see the next generation of biomedical engineers tackle these problems and how their unique skillsets and perspectives can make medical technology better, faster, and less costly.”

NIBIB’s first prize, the Steven H. Krosnick prize, of $20,000 went to the Onchoscope. The team from Stanford University, California developed a low-cost microscope that could help diagnose Onchocerciasis, often called river blindness, a parasitic disease that causes extreme itchiness and, eventually, blindness. It affects more than 20 million people worldwide. The Onchoscope has the ability to diagnose the disease more accurately than the current standard of care and can also be used to monitor the parasitic load over time to evaluate the effectiveness of treatment.

The second prize of $15,000 went to a team from the University of Washington, Seattle for their development of an osmotic concentrator for urinary biomarkers to diagnose tuberculosis (TB).  Confirming a TB diagnosis involves invasive sputum samples, which can be difficult for children and people who are immunocompromised. A urine-based test would be both cheaper and easier to collect. However, because urine is 95% water, there are currently no tests that are sensitive enough to accurately diagnose TB. This new device concentrates urine so that the biomarkers can be detected by lateral flow strip tests.

The third prize of $10,000 went to Duke University, Durham, North Carolina for a low-cost silo used to help save the lives of infants in Sub-Saharan Africa who suffer from gastroschisis, a birth defect where the bowel develops outside the baby’s body.  The silo is a plastic bag with a semi-rigid opening that is used to protect and contain the baby’s internal organs until they can be reintroduced into the abdomen.  Children in high income countries who suffer from gastroschisis have a survival rate of more than 95%. However, babies in Sub-Saharan Africa have a survival rate of less than 10%. This is often because they do not have a dedicated silo for the intestines and instead end up using an intravenous fluid bag or even an examination glove. The device is an affordable alternative that costs less than five dollars and could help drastically increase the survival of children suffering from gastroschisis.

Two additional prizes of $15,000 each were also awarded by NIH. The first, from OAR, was awarded to the CytoScope from Johns Hopkins University, Baltimore. The CytoScope is a low-cost microscope that is able to quickly analyze blood samples to monitor the progression of HIV and warn the patient if the disease has progressed. The relatively low cost of this microscope could help expand the monitoring of HIV/AIDS, especially in low income areas. The second prize, awarded by NIMHD, for the innovative Universal Brachytherapy Applicator “At Your Cervix” was submitted by Rice University. This is a low-cost 3D printed device that could help expand treatment of late-stage cervical cancer in areas where medical providers do not have the training or expertise to administer brachytherapy (radioactive implants).

VentureWell selected two more teams based on two additional criteria: market potential and patentability. The VentureWell Prize of $15,000 went to NeuroTrak, a project from Columbia University, New York. The NeuroTrak is designed to consistently collect electroencephalography (EEG) data in real time to monitor Focal with Impaired Awareness (FIA) seizures. It can increase the accuracy of seizure information over self-reported data and can help doctors make more informed treatment decisions.

The VentureWell Design Excellence Prize awarded $5,000 to a team from Stanford University, California that developed a urine dipstick test to detect acute kidney injuries. Early detection of kidney injury from conditions such as drug-induced nephrotoxicity, septic shock, or dehydration can increase the odds of survival up to five times. This test is a quick, low-cost way to screen for kidney injuries, especially in low-income environments where there may not be adequate testing resources.

"The winners of this year's DEBUT Challenge demonstrated resilience and creativity by creating innovative approaches to addressing significant medical needs despite the challenges of adapting to COVID19 restrictions, often working from their homes and communicating remotely with teammates,” said Phil Weilerstein, President of VentureWell. “Their impressive work reveals them as the entrepreneurial engineers and design innovators that the world needs."


About the National Institute of Biomedical Imaging and Bioengineering (NIBIB): NIBIB’s mission is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care. NIBIB supports emerging technology research and development within its internal laboratories and through grants, collaborations, and training. More information is available at the NIBIB website:

The Office of AIDS Research, part of the Office of the Director, plans and coordinates the scientific, budgetary, legislative and policy elements of the NIH AIDS research program. Additional information, including the trans-NIH strategic plan and budget, is available at

NIMHD leads scientific research to improve minority health and eliminate health disparities by conducting and supporting research; planning, reviewing, coordinating, and evaluating all minority health and health disparities research at NIH; promoting and supporting the training of a diverse research workforce; translating and disseminating research information; and fostering collaborations and partnerships. For more information about NIMHD, visit

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

Filters close

Showing results

110 of 3817
Released: 30-Oct-2020 6:35 PM EDT
UCLA Health infectious disease experts tout critical role mask wearing plays in limiting spread of COVID-19
University of California, Los Angeles (UCLA), Health Sciences

With thousands of new cases logged daily and a vaccine to fight COVID-19 still in development, UCLA Health infectious disease experts are encouraging people to continue to wear masks as the best method of protecting against virus transmission.

Released: 30-Oct-2020 5:35 PM EDT
Surgeon General expects COVID-19 vaccine to be available by year’s end
University of California, Los Angeles (UCLA), Health Sciences

In a wide-ranging talk with UCLA Health physicians, Wednesday, Oct. 28, United States Surgeon General Jerome Adams, MD, MPH, addressed the politicization of the pandemic and the means of containing the spread of COVID-19. He also offered hope that a vaccine for the virus will be available by year’s end.

Released: 30-Oct-2020 4:15 PM EDT
Study shows myocarditis linked to COVID-19 not as common as believed
Louisiana State University Health Sciences Center - New Orleans

A study conducted by Richard Vander Heide, MD, PhD, Professor and Director of Pathology Research at LSU Health New Orleans School of Medicine, and Marc Halushka, MD, PhD, Professor of Pathology at Johns Hopkins University School of Medicine, suggests myocarditis caused by COVID-19 may be a relatively rare occurrence.

access_time Embargo lifts in 2 days
Embargo will expire: 3-Nov-2020 11:00 AM EST Released to reporters: 30-Oct-2020 3:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 3-Nov-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: 247373_web.jpg
Released: 30-Oct-2020 2:30 PM EDT
Researcher develops app to reach Black community with COVID-19 information
University of Cincinnati

A University of Cincinnati cardiologist is partnering with researchers in St. Louis and rural Georgia to develop a smartphone app that will deliver COVID-19 information and education that is targeted toward Black communities.

Newswise: 247467_web.jpg
Released: 30-Oct-2020 1:55 PM EDT
SARS-CoV-2 might attack red marrow and block new erythrocytes formation
Far Eastern Federal University

Specialists from the Department of Fundamental Medicine of Far Eastern Federal University (FEFU) with Russian and Japanese colleagues have probed into mechanisms of COVID-19 inside-the-body distribution linked to erythrocytes damaging. According to researchers, the virus might attack red marrow, thus being detrimental not only for erythrocytes in the bloodstream but also for the process of the formation of the new ones.

Released: 30-Oct-2020 12:40 PM EDT
Government of Canada awards $2.5M to McMaster University to support the COVID-19 border study with McMaster HealthLabs
McMaster University

McMaster University has been awarded $2.5 million from the Government of Canada to support the McMaster HealthLabs (MHL) Canadian International COVID-19 Surveillance Border Study at Toronto Pearson International Airport, being run in partnership with Air Canada and the Greater Toronto Airports Authority (GTAA).

Released: 30-Oct-2020 12:00 PM EDT
5 Big Questions on Health Care and COVID-19
University of Virginia Darden School of Business

The coronavirus pandemic has once again thrust the unusual state of American health care into the spotlight. With a presidential election that could have a dramatic impact on the state of health care for millions on 3 November, Professor Vivian Riefberg considers the state of the industry.

Newswise: Infection by Confection: COVID-19 and the Risk of Trick-or-Treating
Released: 30-Oct-2020 11:05 AM EDT
Infection by Confection: COVID-19 and the Risk of Trick-or-Treating
University of California San Diego Health

Researchers determined that COVID-19 transmission risk via Halloween candies is low, even when they are handled by infected people, but handwashing and disinfecting collected sweets reduces risk even further.

Newswise:Video Embedded third-spike-in-covid-19-cases-plus-the-vaccine-trials-live-expert-panel-for-october-29-3pm-edt
Released: 30-Oct-2020 9:40 AM EDT
TRANSCRIPT AND VIDEO AVAILABLE: "Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29

"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT

Showing results

110 of 3817